|
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
|
Amicus |
|
IPA Feedback Survey: Response to Myozyme Supply Disruption
|
IPA |
|
Pompe Program Update
|
Genzyme |
|
Genzyme Submits All Information Requested by FDA for Lumizyme
|
Genzyme |
|
IPA Statement: The End of Myozyme Supply Restrictions
|
IPA |
|
Pompe Program Update
|
Genzyme |
|
Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
|
Genzyme |
|
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe
|
Amicus |
|
European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme
|
Genzyme |
|
Genzyme Receives Positive Opinion on Myozyme from CHMP in Europe
|
Genzyme |
